Published in final edited form as:

Biochem Biophys Res Commun. 2014 May 23; 448(1): 83–88. doi:10.1016/j.bbrc.2014.04.092.

Enhanced Prostacyclin Formation and Wnt Signaling in Sclerostin Deficient Osteocytes and Bone

Zachary C. Ryan¹, Theodore A. Craig¹, Jeffrey L. Salisbury², Lomeli R. Carpio³, Meghan McGee-Lawrence⁴, Jennifer J. Westendorf^{2,4}, and Rajiv Kumar^{1,2}

¹Division of Nephrology and Hypertension, Department of Medicine, 200 First Street SW, Rochester, MN 55905, USA

²Department of Biochemistry and Molecular Biology, 200 First Street SW, Rochester, MN 55905, USA

³Mayo Graduate School, 200 First Street SW, Rochester, MN 55905, USA

⁴Department of Orthopedic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

Abstract

We show that prostacyclin production is increased in bone and osteocytes from sclerostin (*Sost*) knockout mice which have greatly increased bone mass. The addition of prostacyclin or a prostacyclin analog to bone forming osteoblasts enhances differentiation and matrix mineralization of osteoblasts. The increase in prostacyclin synthesis is linked to increases in β -catenin concentrations and activity as shown by enhanced binding of lymphoid enhancer factor, Lef1, to promoter elements within the *prostacyclin synthase* promoter. Blockade of Wnt signaling reduces prostacyclin production in osteocytes. Increased prostacyclin production by osteocytes from sclerostin deficient mice could potentially contribute to the increased bone formation seen in this condition.

Keywords

Prostacyclin; osteocytes; sclerostin deficiency; Wnt

Introduction

Excessive bone loss causes osteoporosis and enhances susceptibility to fractures, leading to significant morbidity, mortality and excess health care costs [1]. Understanding mechanisms by which bone mass can be enhanced or maintained could result in new strategies effective

© 2014 Elsevier Inc. All rights reserved.

Correspondence to: Rajiv Kumar, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Telephone: 507-284-0020; Fax: 507-538-3954; rkumar@mayo.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

in increasing or preserving skeletal integrity and promoting fracture healing, thus reducing costs and co-morbidities associated with osteoporosis and fractures.

The balance between bone loss and deposition is important for normal bone growth and remodeling, and depends on a complex regulatory interplay among resident bone cells such as osteoclasts, osteoblasts, and osteocytes whose activities are altered by serum concentrations of hormones such as parathyroid hormone and $1\alpha,25$ -dihydroxyvitamin D, and several regulatory proteins such as bone morphogenetic proteins, receptor activator of nuclear factor κ -B ligand (RANKL), and lipid mediators such as prostaglandins produced by such cells [2,3,4,5,6,7,8,9]. Previous work demonstrated that the prostaglandin PGE₂ can either increase bone formation and osteoblastic activity [10] or increase bone resorption [11] depending on experimental conditions. The prostaglandin, PGI₂ or prostacyclin also alters bone formation and bone resorption depending on the experimental model [12,13,14,15,16,17,18,19,20]. Deletion of prostacyclin synthase, the enzyme responsible for prostacyclin synthesis, results in a decrease in bone mineral density in young mice and an increase in bone mineral density in older mice [14].

Human patients and mice with inactivating mutations of the sclerostin (*SOST*, *Sost*) gene have significantly increased bone density [7,21,22]. The *Sost* gene product, sclerostin, is a secreted glycoprotein that alters Wnt, bone morphogenetic protein and other signaling pathways [23,24,25,26,27]. We previously examined the mechanisms by which bone mass is increased in a novel sclerostin-deficient mouse model [21] which shows an exceptionally dense skeleton and rapid fracture healing [28]. We now show that the production of prostacyclin (PGI₂), a cyclic prostanoid, is greatly increased in bone and osteocytes of sclerostin-deficient mice. We demonstrate that prostacyclin, and a prostacyclin analog, increase osteoblast differentiation and mineralization. In the absence of sclerostin production, β -catenin activity in osteocytes is increased, and PGI₂ production is influenced by Wnt signaling pathways.

Materials and Methods

Animal Studies

Animal research was conducted according to National Institutes of Health and the Institute of Laboratory Animal Resources, National Research Council guidelines. The Mayo Clinic Institutional Animal Care and Use Committee approved all animal studies.

Generation of *Sost* Knock-out mice

Mice were generated as described earlier [21].

Isolation of Osteocytes from Mouse Femurs

Osteocytes were isolated from 8-week-old *Sost* KO and WT mice as described by Stern et al. [29].

Immortalization of Osteocytes

Osteocytes were immortalized using an SV40 T antigen viral construct as described earlier [30]. Clonal populations of osteocytes from *Sost* KO and WT mice were generated via dilution cloning.

Preparation of Decalcified Bone for Immunohistochemistry

Femurs were isolated and sectioned as described earlier [21,28]. Immunohistochemistry was performed with antibodies to prostaglandin I₂ synthase (Cayman Chemical, 1:50 dilution), or with an IgG isotype control (Vector Laboratories I-1000). Chromogens were developed using a polyvalent mouse and rabbit specific secondary HRP detection kit (Abcam), followed by incubation in 3,3-diaminobenzidine.

Measurement of Prostaglandins

Prostaglandin (6-Keto PGF₁ α , PGE₂, PGE Metabolite, PGF₂ α , PGD₂, and TBXB₂) measurements were performed in bone extracts, 24 hour urine samples, and cell lysates by enzyme immunoassay (EIA) using kits from Cayman Chemical (Ann Arbor, MI).

Microscopy (E11/podoplanin, Lef1, β -Cat Staining)

WT and *Sost* KO osteocytes were grown on 12-well, collagen treated, glass bottom plates (MatTek Corporation). Cells were fixed in 4% PFA, washed in PBS, and blocked in 10% goat serum in PBS. The following primary antibodies were used: podoplanin (8.1.1, Santa Cruz Biotechnology, 1:50 dilution), Lef-1 (N-17, Santa Cruz Biotechnology, 1:50 dilution), β -catenin (Cell Signaling Technologies, 1:1000 dilution). After several PBS washes, secondary antibody was added. For podoplanin: Alexa Fluor 488-labeled goat anti-hamster IgG, 1:200 dilution; for Lef-1: Alexa Fluor 488-labeled donkey anti-goat IgG, 1:200 dilution; for β -catenin: AlexaFluor 594-labeled goat anti-rabbit IgG, 1:200 dilution (all from Life Technologies). Cells were washed with PBS, and counterstained with Vectashield Hard Set Mounting Medium containing 4',6-diamidino-2-phenylindole (Vector Laboratories). Cells were photographed on an Axio Observer inverted microscope; fluorescence micrographs were taken using a Zeiss Super Resolution Elyra microscope system with Structured Illumination and a Plan-Apochromat 63X/1.4NA oil objective controlled by ZEN 2010 software.

C59 Inhibitor Experiments

Serum-free medium (α -MEM, 1% P/S) containing either 100 nM Wnt inhibitor, C59 (2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridine-3-yl)phenyl) acetamide) or vehicle, was added to cultures of *Sost* knockout osteocytes for 48-hours. 6-keto PGF₁ α was measured in the medium.

SDS-PAGE and Immunoblot Analyses

Cell lysates were electrophoresed, transferred to PVDF membranes which were blocked and probed with primary antibodies in 5% BSA, TBST: 1:1000 dilutions of antibodies recognizing non-phosphorylated (active) β -catenin, all β -catenin forms, phosphorylated Ser33/37/Thr41- β -catenin (all from Cell Signaling Technology, Inc.), or 1:1500 dilution

prostaglandin I synthase polyclonal antibody made in rabbit (Cayman Chemical). After washing with TBST, 1:2000 dilution horseradish peroxidase labeled goat anti-rabbit secondary antibody in 0.5× Roche block/TBST was applied and blots were visualized using chemiluminescent substrate (Roche). PVDF membranes also probed with a β -actin monoclonal antibody (I2E5) (Cell Signaling Technologies). Densitometric analysis of scanned X-ray films from chemiluminescent detection was performed using ImageJ (NIH).

RT-PCR Analyses of Osteocyte Markers

Reverse transcription of isolated RNAs was carried out using oligo(dT) primers and SuperScript® III First-Strand Synthesis System for RT-PCR. (Life Technologies). PCR for osteocyte markers was carried out using platinum TAQ polymerase (Life Technologies) and appropriate intron spanning primers designed using the Roche Universal Probe Library Assay Design Center (Roche) (**Supplemental Table 1**). PCR reactions were electrophoresed on 4% agarose gels that were later stained with ethidium bromide.

RNA preparation for RNA-seq and QPCR

RNA was prepared using RNA/protein spin columns (Clontech). Lysis solution was added to cells, frozen cell pellets or frozen bone powder. Individual clarified lysates were purified on RNA spin columns. Eluted RNA was characterized by UV absorbance (absorbance 260 nm/280 nm ratio), quantitated and frozen at -80°C .

Quantitative PCR

qPCR was carried out using a Roche LightCycler 480 QPCR apparatus using intron-spanning qPCR primer pairs for mouse genes (Roche) (**Supplemental Table 2**). A SuperscriptIII RT-PCR kit (Life Technologies) was used to generate template DNA from RNA. Reverse transcribed Superscript III product was used to generate PCR products with each primer pair. Product was used to generate standard QPCR curves. QPCR data were quantitated against murine Rpl13a run for each primer pair.

Chromatin Immunoprecipitation (ChIP) Assays

ChIP assays were performed as described earlier [31] on osteocytes isolated from WT and *Sost* KO mice. Immunoprecipitations were performed with 2 μg Lef1-specific antibody or an isotype-matched IgG control (Millipore). Purified DNA was added to PCRs containing primers (5'-GCACTGAGACACGGGAAGA-3' and 5'-GTCTCTGCCTCCCAAGCTC-3') that flank the putative Lef1 binding site identified in the *Ptgis* promoter (5'-CCTTTTGAT-3', beginning 1860 bp upstream of the translational initiation codon). ChIP DNA was measured by real-time PCR, with threshold values normalized to input DNA and the isotype control immunoprecipitation.

Mineralization Studies

These were performed as described earlier [32]. MC3T3 cells (1×10^4 cells/well) were seeded in 24-well plates. Upon confluence, ascorbic acid (100 $\mu\text{g}/\text{mL}$) was added. After 72 hours, 5mM β -glycerophosphate, $^{45}\text{CaCl}_2$ (18.5 kBq/well), and either vehicle (PBS), prostacyclin (10 μM), or carbaprostacyclin (10 μM) were added. Vehicle, prostacyclin

(10 μ M) or carbaprostacyclin (10 μ M) were added daily, and media were changed every 3.5 days. At days 7 and 14 post-addition of β -glycerophosphate, cells were rinsed with PBS, and frozen at -20°C . Frozen cells were lysed with 500 μ L of 10mM Tris-HCl (pH 7.4), 10mM MgCl_2 , and 0.1% (w/v) Triton X-100, and centrifuged at 14,000 $\times$ g for 5 minutes. Alkaline phosphatase activity was measured by fluorescence assay (QuantiFluo, BioAssay Systems) in the supernatant. Radioactivity (^{45}Ca) was measured with a TopCount NXT (Perkin Elmer) scintillation counter by adding 50 μ L of the cell lysate to 150 μ L of scintillant (Microscint 40).

Statistical Methods

Statistical differences between samples were analyzed using Student's two-tailed *t*-test assuming equal variance. $P < 0.05$ was regarded as statistically significant.

Results

Arachidonic acid (AA), the precursor to prostaglandins, is converted via the cyclooxygenase pathway to prostaglandin PGG_2 and subsequently to PGH_2 [33]. The latter is converted to PGI_2 , PGD_2 , PGE_2 , PGF_2 and thromboxane A_2 by specific synthases; PGF_2 is also directly produced from PGE_2 [33]. In femoral bone extracts, higher concentrations of 6-keto $\text{PGF}_{1\alpha}$, the stable metabolite of PGI_2 , were detected in bone from *Sost* KO mice compared with those measured in WT mice (**Figure 1A**). Concentrations of PGE_2 , PGD_2 , TXB_2 (the stable metabolite of TXA_2) and $\text{PGF}_{2\alpha}$, were similar in *Sost* KO and WT mice (**Figure 1A**). Messenger RNA levels for the enzyme, *PGI*₂ synthase (*Ptgis*), were increased while mRNAs for *PGE*₂ synthase (*Ptges*) and thromboxane A synthase 1 (*Tbxas1*) remained unchanged in bone extracts from *Sost* KO and WT mice (**Figure 1B**). The increase in prostacyclin and *Ptgis* mRNA was associated with an increase in prostacyclin synthase protein (*Ptgis*) in osteocytes of bones from *Sost* KO mice relative to osteocytes of bones from WT mice (**Figure 1C**). Levels of urinary prostaglandin metabolites were similar in *SOST* KO and WT mice (ng/mL prostaglandin/mg urinary creatinine; mean $\pm$ SEM: KO vs. control: 6-keto $\text{PGF}_{1\alpha}$, 27.74 ± 4.55 vs. 24.15 ± 2.22 , $P = 0.241$; PGE , 21.22 ± 5.7 vs. 27.80 ± 4.22 , $P = 0.391$; PGD_2 , 149.04 ± 11.86 vs. 132.52 ± 35.69 , $P = 0.683$; $\text{PGF}_{2\alpha}$, 9.04 ± 2.05 vs. 21.47 ± 4.35 , $P = 0.061$; and TBXB_2 23.56 ± 3.79 vs. 28.08 ± 3.65 , $P = 0.830$).

We established primary and immortalized osteocyte cultures to determine whether the high bone prostacyclin content in *Sost* KO mice was produced in the bone cells that normally express sclerostin. 6-keto $\text{PGF}_{1\alpha}$ was increased 3-fold in primary osteocytes isolated from bone of *Sost* KO compared to WT mice (93.68 ± 23.39 vs. 31.24 ± 8.44 pg 6-keto $\text{PGF}_{1\alpha}$ /mg protein, $P = 0.024$), whereas PGE_2 concentrations were similar (1.52 ± 0.37 vs. 1.94 ± 0.47 pg PGE_2 /mg protein, $P = 0.52$). In mixed populations of immortalized osteocytes, concentrations of 6-keto $\text{PGF}_{1\alpha}$ were increased in *Sost* KO compared to WT osteocytes ($2,823.51 \pm 485.64$ pg/mL KO vs. 163.41 ± 10.49 pg/mL WT, $P = 0.005$), whereas PGE_2 concentrations were similar. These changes are mirrored by the increase of mRNA for *Ptgis* by 100-fold, $P < 0.001$, in *Sost* KO osteocytes compared to WT osteocytes. A 1.7-fold increase in *Ptges* mRNA was also observed, $P < 0.001$. Prostaglandin production in clonal populations of *Sost* KO (KO8) and WT (WT12) osteocytes showed a substantial

increase in 6-keto PGF_{1α} in *Sost* KO8 compared to WT12 cultures ($3,302.41 \pm 27.97$ pg/mL vs. 178.89 ± 66.49 pg/mL, $P < 0.001$, respectively), whereas PGE₂ concentrations were only slightly but statistically higher in *Sost* KO8 ($1,298.9 \pm 43.3$ pg PGE₂/mL vs. $1,093.2 \pm 31.2$ pg PGE₂/mL, $P = 0.003$). The mRNA for *Ptgis* increased > 400-fold, $P = < 0.001$. A considerably smaller, 13-fold change in *Ptges* mRNA was also observed, $P = < 0.001$. *Ptgis* protein is increased in *Sost* KO8 osteocytes compared to WT12 osteocytes by western blotting.

Previous experiments have shown that prostacyclin enhances bone mineralization and osteoblast enzymatic function. To further assess the role of prostacyclin in osteoblast differentiation and mineralization, we treated MC3T3 osteoblasts with prostacyclin or carbaprostacyclin. Alkaline phosphatase activity was enhanced in MC3T3 osteoblast-like cells at 14 days after the exogenous addition of prostacyclin or carbaprostacyclin (**Figure 2A**). There was an increase in *Alpl* mRNA in treated cells at day 14 (ratio *Alpl* in PGI₂ or vehicle treated cells = 1.46, $P = 0.037$; carbaPGI₂ or vehicle treated cells = 1.43, $P = 0.006$). Mineralization assessed by the uptake and deposition of ⁴⁵Ca in matrix was enhanced in cells treated with prostacyclin or carbaprostacyclin when compared to vehicle (**Figure 2B**).

To determine whether Wnt signaling was responsible for changes in prostacyclin expression in *Sost* KO osteocytes, we assessed expression and localization of β-catenin in *Sost* KO8 and WT12 osteocyte clones. We found a 2-fold ($P < 0.001$) increase in β-catenin mRNA and a corresponding 6-fold ($P < 0.001$) increase in total β-catenin in *Sost* KO8 compared to WT12 (**Figure 3A and B**). *Sost* KO8 cells showed a nearly 9-fold ($P = 0.013$) increase in the non-phosphorylated, active form of β-catenin. While both WT12 and KO8 cells showed cytoplasmic and cell membrane associated β-catenin, the increased protein level in *Sost* KO8 cells was accompanied by a substantial increase in nuclear β-catenin (**Figure 3C, D**). The nuclear β-catenin showed predominantly euchromatic co-localization with a Wnt effector protein, lymphocyte enhancer protein (Lef1) (**Figure 3F₁₋₅**). WT12 osteocytes showed substantially less nuclear β-catenin and virtually undetectable nuclear Lef1 (**Figure 3E₁₋₅**).

To determine if increased Lef1 localization on chromatin influenced *Ptgis* gene function, we performed chromatin immunoprecipitation experiments using *Sost* KO8 and WT12 cells, and a specific antibody against Lef1, to localize Lef1 binding sites on the *Ptgis* gene. A Lef-binding site was found using *in silico* analysis at -1860 bp to -1853 bp upstream of the translation initiation site of the *Ptgis* gene promoter. Chromatin immunoprecipitation with a Lef1 antibody, followed by real-time PCR performed with primers flanking this site, showed higher Lef1 occupancy of this site in *Sost* KO8 as compared to WT12 osteocytes (**Figure 4**).

The functional importance of β-catenin signaling in sclerostin-mediated increases in PGI₂ synthesis was assessed by treating *Sost* KO8 cells with a Wnt inhibitor, C59 (2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4(pyridine-3-yl)phenyl)acetamide). Following treatment of cells with C59 there was a decrease in βcatenin protein concentrations in *Sost* KO8 osteocytes ($P < 0.05$), as well as a concomitant decrease in 6-keto PGF_{1α} (536.41 ± 60.69 pg/mL vehicle vs 274.96 ± 6.01 pg/mL experimental, $P = 0.013$).

Discussion

Relative rates of bone formation and resorption determine the amount of mineralized bone present in the skeleton. These processes are under cellular control and the activities of osteoblasts and osteoclasts that form and resorb bone, respectively, are dependent on physiological needs and mechanical stimulation. Among the physiological regulators are endocrine factors, such as parathyroid hormone and 1 α ,25-dihydroxyvitamin D and the availability of calcium and phosphorus in the extra-cellular fluid. The activity of several locally produced peptides (e.g. RANKL and the BMPs) and lipid mediators (e.g. PGE₂) whose concentrations and activities are influenced by the aforesaid systemic hormones and factors such as mechanical force and fluid flow are also crucial [2,3,4,5,6,7,8,9,34,35,36,37,38].

With regard to the effects of prostanoids on bone, previous reports demonstrated that PGE₂ is released from bone cells in response to changes in fluid flow [39] and that PGE₂ increases bone mass when administered to rodents [10]. The observation that the production of prostacyclin or PGI₂, a prostaglandin previously only shown to play a role in modulating platelet, vascular and immune function [33,40,41,42,43], is greatly increased in bones and osteocytes of sclerostin-deficient mice suggests that this short-lived prostanoid contributes to bone formation in the context of this high bone mass syndrome. The effectiveness of prostacyclin in enhancing osteoblast maturation, as evidenced by increases in alkaline phosphatase expression and mineralization of osteoblast cultures treated with exogenous prostacyclin, indicates that prostacyclin may be effective in increasing bone mass in the normal bone as well.

We demonstrate the expression of prostaglandin synthase, the enzyme responsible for the synthesis of prostacyclin, is regulated by β -catenin and its downstream effector, Lef-1, which binds to the *Ptgis* promoter and increases *Ptgis* mRNA. In *Sost* KO mice, enhanced bone formation has been attributed to increased availability of the Wnt/frizzled pathway co-receptor, LRP 5/6, which facilitates activation of Wnt pathways and β -catenin stabilization when Wnt ligands are present [28]. The work presented here suggests that prostanoid metabolism is regulated by Wnts and β -catenin and may contribute to high bone mass in sclerostin deficient mice.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The NIH (R01 DE020194, AR60869, T32 AR056950, F32 AR60140,) a grant from the Dr. Ralph and Marion Falk Foundation.

References

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *Journal of bone and*

mineral research : the official journal of the American Society for Bone and Mineral Research. 2007; 22:465–475.

2. DeLuca HF, Schnoes HK. Vitamin D: recent advances. Annual review of biochemistry. 1983; 52:411–439.
3. Raisz LG, Kream BE. Hormonal control of skeletal growth. Annual review of physiology. 1981; 43:225–238.
4. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinoshita M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95:3597–3602. [PubMed: 9520411]
5. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990; 345:442–444. [PubMed: 2188141]
6. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends in endocrinology and metabolism: TEM. 2010; 21:294–301. [PubMed: 20079660]
7. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foerzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10:537–543. [PubMed: 11181578]
8. Sampath TK, Muthukumaran N, Reddi AH. Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84:7109–7113. [PubMed: 3478684]
9. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242:1528–1534. [PubMed: 3201241]
10. Jee WS, Ke HZ, Li XJ. Long-term anabolic effects of prostaglandin-E2 on tibial diaphyseal bone in male rats. Bone and mineral. 1991; 15:33–55. [PubMed: 1747567]
11. Raisz LG, Sandberg AL, Goodson JM, Simmons HA, Mergenhagen SE. Complement-dependent stimulation of prostaglandin synthesis and bone resorption. Science. 1974; 185:789–791. [PubMed: 4843377]
12. Bennett A, Edwards D, Ali NN, Auger D, Harris M. Prostacyclin potently resorbs bone in vitro. Advances in prostaglandin and thromboxane research. 1980; 6:547–548. [PubMed: 6992541]
13. Glantschnig H, Varga F, Rumpler M, Klaushofer K. Prostacyclin (PGI₂): a potential mediator of c-fos expression induced by hydrostatic pressure in osteoblastic cells. European journal of clinical investigation. 1996; 26:544–548. [PubMed: 8864415]
14. Nakalekha C, Yokoyama C, Miura H, Alles N, Aoki K, Ohya K, Morita I. Increased bone mass in adult prostacyclin-deficient mice. The Journal of endocrinology. 2010; 204:125–133. [PubMed: 19906840]
15. Partridge NC, Kemp BE, Veroni MC, Martin TJ. Activation of adenosine 3',5'-monophosphate-dependent protein kinase in normal and malignant bone cells by parathyroid hormone, prostaglandin E₂, and prostacyclin. Endocrinology. 1981; 108:220–225. [PubMed: 6257486]
16. Raisz LG, Vanderhoek JY, Simmons HA, Kream BE, Nicolaou KC. Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin. Prostaglandins. 1979; 17:905–914. [PubMed: 388530]
17. Rawlinson SC, Mohan S, Baylink DJ, Lanyon LE. Exogenous prostacyclin, but not prostaglandin E₂, produces similar responses in both G6PD activity and RNA production as mechanical loading, and increases IGF-II release, in adult cancellous bone in culture. Calcified tissue international. 1993; 53:324–329. [PubMed: 7506987]
18. Robin JC, Brown MJ, Weinfeld N, Dziak R. Prostacyclin: effects on cyclic AMP in bone cells. Research communications in chemical pathology and pharmacology. 1982; 35:43–49. [PubMed: 6276954]

19. Tuncbilek G, Korkusuz P, Ozgur F. Effects of iloprost on calvarial sutures. *The Journal of craniofacial surgery*. 2008; 19:1472–1480. [PubMed: 19098535]
20. Walenga RW, Bergstrom W. Stimulation of calcium uptake in rat calvaria by prostacyclin. *Prostaglandins*. 1985; 29:191–202. [PubMed: 3920727]
21. Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:6199–6204. [PubMed: 23530237]
22. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. *J Bone Miner Res*. 2008; 23:860–869. [PubMed: 18269310]
23. Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. *Development*. 2008; 135:3801–3811. [PubMed: 18927151]
24. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. *J Biol Chem*. 2003; 278:24113–24117. [PubMed: 12702725]
25. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpекtor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. *Embo J*. 2003; 22:6267–6276. [PubMed: 14633986]
26. Craig TA, Bhattacharya R, Mukhopadhyay D, Kumar R. Sclerostin binds and regulates the activity of cysteine-rich protein 61. *Biochem Biophys Res Commun*. 2010; 392:36–40. [PubMed: 20043874]
27. Craig TA, Kumar R. Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin. *Biochem Biophys Res Commun*. 2010; 402:421–424. [PubMed: 20951118]
28. McGee-Lawrence ME, Ryan ZC, Carpio LR, Kakar S, Westendorf JJ, Kumar R. Sclerostin deficient mice rapidly heal bone defects by activating beta-catenin and increasing intramembranous ossification. *Biochemical and biophysical research communications*. 2013; 441:886–890. [PubMed: 24211207]
29. Stern AR, Stern MM, Van Dyke ME, Jahn K, Prideaux M, Bonewald LF. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. *BioTechniques*. 2012; 52:361–373. [PubMed: 22668415]
30. Nagel D, Kumar R. 1 alpha,25-dihydroxyvitamin D3 increases TGF beta 1 binding to human osteoblasts. *Biochemical and biophysical research communications*. 2002; 290:1558–1563. [PubMed: 11820800]
31. McGee-Lawrence ME, Li X, Bledsoe KL, Wu H, Hawse JR, Subramaniam M, Razidlo DF, Stensgard BA, Stein GS, van Wijnen AJ, Lian JB, Hsu W, Westendorf JJ. Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice. *J Biol Chem*. 2013; 288:5291–5302. [PubMed: 23300083]
32. Davis J, Cook ND, Pither RJ. Biologic mechanisms of 89SrCl2 incorporation into type I collagen during bone mineralization, *Journal of nuclear medicine : official publication. Society of Nuclear Medicine*. 2000; 41:183–188.
33. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. *Annual review of biochemistry*. 1978; 47:997–1029.
34. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:20764–20769. [PubMed: 19075223]
35. Sampath TK, Reddi AH. Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. *Proceedings of the National Academy of Sciences of the United States of America*. 1983; 80:6591–6595. [PubMed: 6579546]

36. Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wozney JM. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. *Proceedings of the National Academy of Sciences of the United States of America*. 1990; 87:9843–9847. [PubMed: 2263636]
37. Rosen V, Thies RS. The BMP proteins in bone formation and repair. *Trends in genetics : TIG*. 1992; 8:97–102. [PubMed: 1579995]
38. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, et al. Recombinant human bone morphogenetic protein induces bone formation. *Proceedings of the National Academy of Sciences of the United States of America*. 1990; 87:2220–2224. [PubMed: 2315314]
39. Zaman G, Suswillo RF, Cheng MZ, Tavares IA, Lanyon LE. Early responses to dynamic strain change and prostaglandins in bone-derived cells in culture. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 1997; 12:769–777.
40. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature*. 1976; 263:663–665. [PubMed: 802670]
41. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. *Nature reviews. Drug discovery*. 2003; 2:879–890.
42. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowitz JB. Arachidonic acid metabolism. *Annual review of biochemistry*. 1986; 55:69–102.
43. Weksler BB. Prostaglandins and vascular function. *Circulation*. 1984; 70:III63–71. [PubMed: 6386223]

Highlights

- Prostacyclin is increased in bone and osteocytes from sclerostin knockout mice.
- Prostacyclin enhances differentiation and matrix mineralization of osteoblasts.
- Increased osteocyte prostacyclin associates with increased β -catenin activity.
- Blockade of Wnt signaling reduces prostacyclin production in osteocytes.

Figure. 1.

Prostaglandins, mRNAs for prostaglandin synthases, and prostacyclin synthase in extracts of bones or decalcified bone sections of *Sost* WT or KO mice. **A.** Concentrations of prostaglandins in bone. **B.** Concentrations of mRNA transcripts for the PG synthases. **C.** *Ptgis* in osteocytes present in decalcified bone sections from *Sost* KO (lower right panel) mice and *Sost* WT mice (upper right panel).

Figure 2.

Effect of prostacyclin and carbaprostacyclin on differentiation and mineralization of MC3T3 osteoblasts. **A.** Alkaline phosphatase activity in cells at 7 days and 14 days in the presence of vehicle, PGI₂ or carbaPGI₂. **B.** ⁴⁵Ca uptake in cells and matrix at 7 days and 14 days in the presence of vehicle, PGI₂ or carbaPGI₂. * P < 0.05, ** P < 0.001.

Figure 3.

β-catenin protein and mRNA and Lef1 protein in clonal osteocytes from *Sost* KO and WT mice. **A. Upper panel.** Immunoblot of cellular protein from WT (left 4 lanes in panel) and KO (right 4 lanes in panel) clonal osteocytes with total β-catenin specific antibody. **Lower panel.** Immunoblot of cellular protein from WT (left 4 lanes in panel) and KO (right 4 lanes in panel) clonal osteocytes with non-phosphorylated (active) β-catenin specific antibody. **B.** Assessment of β-catenin transcript levels in WT and KO clonal osteocytes. **C.** β-catenin immunofluorescence (IF, red) in WT osteocyte. The nucleus of the cell is stained blue. **D.** β-catenin IF (red) in KO osteocyte. The nucleus of the cell is stained blue. **E. Panels 1-5,** localization of β-catenin (red, **panel 4**) and Lef1 (green, **panel 5**) in the nucleus of a clonal *Sost* WT osteocyte. In **panel 2** and **3**, co-localization of β-catenin and Lef1 are shown. **F, panels 1-5,** localization of β-catenin (red, **panel 4**) and Lef1 (green, **panel 5**) in the nucleus of a clonal *Sost* KO osteocyte. In **panel 2** and **3**, co-localization of β-catenin and Lef1 are shown. More intense IF is noted in the clonal KO than in the WT clonal osteocytes. This is especially apparent in panels **F3** vs. **E3**.

Figure 4. ChIP analysis of the *Lef1* sites of WT12 and *Sost* KO8 osteocytes. Total percent input of both clones, and associated mouse IgG controls.